Cholangiocarcinoma News

Highlighting New Research on Next- Generation Agents in the Treatment of Cholangiocarcinoma and Other Biliary Cancers

June/July 2022, Vol 3, No 2
Milind M. Javle, MD
Hubert L. and Olive Stringer Professor
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas
M.D. Anderson Cancer Center
Houston, TX
NCI Task Force: Hepatobiliary Cancers

Dear readers,

The publication of the TOPAZ-1 trial in the June 1, 2022 issue of NEJM Evidence marks a milestone in the treatment of biliary tract cancers. Although many questions remain, including those pertaining to predictive biomarkers, heterogeneity of cancer types, underlying risk factors and their correlation with clinical outcome, this article clearly heralds the role of immunotherapy in the management of these cancers.

In this issue of CCA News, we are highlighting 2 important conferences: the Cholangiocarcinoma Foundation (CCF) annual meeting and the International Hepato-Pancreato-Biliary Association (IHPBA) World Congress. In the CCF annual meeting, Dr Rachna Shroff from the University of Arizona highlighted the ongoing development of targeted therapeutics. These include novel IDH1 and FGFR inhibitors, bispecific antibodies, and antibody–drug conjugates directed against HER2/neu as well as NRG1, MDM2, and DNA repair-directed therapeutics. These represent the next generation of agents in these cancers, again highlighting the fact that biliary cancers, particularly cholangiocarcinomas (CCAs), are “target-enriched.” Molecular testing is critical in the management of these cancers and, in an insightful review, Drs May Cho and Sepideh Gholami from the University of California, Irvine highlight the problems associated with biomarker testing in CCA and propose practical solutions, including standardized guidelines, molecular tumor boards, and establishment of a leadership structure, to capture molecular data on most/all biliary tract cancer patients.

The IHPBA meeting presented several studies that highlighted multidisciplinary management. Dr Flavio Rocha, from Oregon Health and Sciences University, highlighted early-stage gallbladder cancer and noted that laparoscopic resection may substitute for open procedures for select cases with early-stage disease. Other highlights included the increasing use of neoadjuvant chemotherapy for intrahepatic CCA in the United States with corresponding lower-margin positivity rates and the need for neoadjuvant chemoradiation prior to liver transplantation for perihilar CCA.

Finally, Dr Reham Abdel-Wahab from the CCF reported the results of a research survey conducted at the CCF annual meeting. Among this group of informed participants, 77% received molecular profiling but only 27% enrolled in clinical trials. Although these figures are somewhat disappointing, they compare favorably with some of the more common solid tumors! These and other important investigations are included in this issue.


Milind M. Javle, MD

Related Items

Exciting New Abstracts from the ASCO GI Cancers Symposium
By Milind M. Javle, MD
March 2023, Vol 4, No 1
Dr Javle provides his perspective on important abstracts presented at the ASCO Gastrointestinal Cancers Symposium, held January 19-21, 2023, in San Francisco, CA.
Highlights from the Fourth Annual CCA Summit
By Milind M. Javle, MD
December 2022, Vol 3, No 4
We have recently concluded the 4th Annual CCA Summit, which was held on October 13-15, 2022, in Denver, Colorado.
New Standard of Care Emerging for Treatment of BTCs
By Milind M. Javle, MD
September 2022, Vol 3, No 3
On September 2, 2022, the US Food and Drug Administration approved durvalumab in combination with gemcitabine/cisplatin for advanced biliary tract cancers (BTCs) on the basis of the TOPAZ-1 study.
Rapid Trajectory of Clinical Research in Biliary Tract Cancers
By Milind M. Javle, MD
March 2022, Vol 3, No 1
The 2022 ASCO GI Cancers Symposium clearly highlighted the rapid trajectory of clinical research in biliary tract cancers. One of the most eagerly anticipated studies, TOPAZ-1, was presented by Do-Youn Oh, MD, PhD, from Seoul National University Hospital in South Korea. This phase 3 clinical trial enrolled 685 patients and investigated the addition of the PD-L1–directed agent durvalu­mab to gemcitabine and cisplatin chemotherapy backbone versus these chemotherapies alone. The results demonstrated a statistically significant improvement in overall survival (OS), overall response rate (ORR), and progression-free survival (PFS), without dose-limiting toxicities.
Hot Topics at ASCO-GI 2022
By Milind M. Javle, MD
Dr Milind Javle provides his perspectives on key presentations on cholangiocarcinoma and biliary tract cancer at the 2022 ASCO Gastrointestinal Cancers Symposium.
Cholangiocarcinoma Research Continues to Thrive
By Milind M. Javle, MD
December 2021, Vol 2, No 4
The Third CCA Summit was held on October 21-22, 2021 in New Orleans. For the majority of the cholangiocarcinoma (CCA) community, this was their first “live” meeting since the pandemic.
Mechanisms of Resistance to FGFR Inhibitors
By Jesús Bañales, PhD; Antoine Hollebecque, MD; Milind M. Javle, MD; Angela Lamarca, MD, PhD, MSc
Drs Javle, Bañales, and Hollebecque discuss the innate and acquired resistance pathways to FGFR inhibitors in cholangiocarcinoma and how these pathways can have important effects on clinical outcomes. They also look ahead to ongoing clinical trials evaluating next-generation FGFR inhibitors that may be able to overcome resistance mechanisms and improve progression-free and overall survival in cholangiocarcinoma.
Molecular Profiling Should Now Be Routine Practice in Patients with CCA
By Milind M. Javle, MD
September/October 2021, Vol 2, No 3
This issue of CCA News features yet another exciting FDA approval for cholangiocarcinoma (CCA), ivosidenib, which was recently approved for CCA with IDH1 mutation. This is the third drug approved for CCA in the past 2 years, highlighting the critical role of molecular profiling in this cancer. Up to 20% of patients with intrahepatic CCA have IDH1 mutation, and the ClarIDHy phase 3 study demonstrated improvement in progression-free survival with ivosidenib versus placebo for chemorefractory disease. The FDA also approved the Oncomine Dx Target Test for IDH1 mutations.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: